2. Academic Validation
  3. A New Chemical Probe Challenges the Broad Cancer Essentiality of CK2

A New Chemical Probe Challenges the Broad Cancer Essentiality of CK2

  • Trends Pharmacol Sci. 2021 May;42(5):313-315. doi: 10.1016/j.tips.2021.02.002.
Marco P Licciardello 1,  Paul Workman 2
Affiliations

Affiliations

  • 1 Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • 2 Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK. Electronic address: paul.workman@icr.ac.uk.
PMID: 33771354 DOI: 10.1016/j.tips.2021.02.002
Abstract

Casein Kinase 2 (CK2) is highly expressed in Cancer and has been considered a potential therapeutic target. Wells and colleagues developed and characterized the new CK2 Inhibitor SGC-CK2-1. Unexpectedly, this potent and highly selective chemical probe does not show broad antiproliferative activity in Cancer cells.

Keywords

COVID-19; cancer; drug target; neurodegenerative diseases; protein kinase; selective CK2 inhibitor.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z